Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Bayer's stock price increase by more than 10% within one week after ESC Congress results presentation?
Yes • 50%
No • 50%
Stock market data from financial news websites such as Bloomberg or Yahoo Finance
Bayer's Finerenone Achieves Primary Endpoint in Phase III HFmrEF and HFpEF Study
Aug 5, 2024, 06:40 AM
Bayer has announced that its Phase III FINEARTS-HF cardiovascular outcomes study investigating KERENDIA® (finerenone) in patients with heart failure with mildly reduced or preserved ejection fraction has achieved its primary endpoint. The study showed that finerenone, a non-steroidal MRA, demonstrated definitive cardiovascular benefits in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF), including reductions in CVd+total HF events. The results are seen as key to unlocking blockbuster sales for the drug. Full results will be presented at the upcoming ESC Congress.
View original story
Increase by 5% or more • 25%
No significant change • 25%
Decrease by up to 5% • 25%
Decrease by more than 5% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
Jardiance (Boehringer Ingelheim) • 25%
Entresto (Novartis) • 25%
Other • 25%
Farxiga (AstraZeneca) • 25%